Neurosense Therapeutics is trading 6.72% up at $0.41 after an overnight move with no confirmed company-specific catalyst.
- A special shareholder meeting is scheduled for August 26, 2026, to consider reverse-split authorization.
- Recent company updates concern PrimeC’s planned December 2026 Health Canada filing, not a new announcement.
- The move may reflect biotech-sector momentum, but broader indices are mixed and no direct cause is confirmed.